Progress Life Sciences Pvt. Ltd. is a linagliptin manufacturers in India. Exporter | Suppliers in India and Middle East
We are a linagliptin Manufacturer, Exporter, Supplier, Distributor, Trader and Exporter of High-Quality API, Lornoxicam, Ethyl Oleate,
Our main Export in Markets, Africa, Middle East, South, Latin America, Southeast Asia, SAARC, Pakistan and Bangladesh are dealers.
Looking for linagliptin Manufacturers ,Suppliers, Exporters best in India?
It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is used together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.
Common side effects include inflammation of the nose and throat. Serious side effects may include angioedema, pancreatitis, joint pain. Use in pregnancy and breastfeeding is not recommended. Linagliptin is a dipeptidyl peptidase-4 inhibitor. It works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.
Linagliptin was approved for medical use in the United States in 2011. In 2018, it was the 177th most commonly prescribed medication in the United States, with more than 3 million prescriptions.
3Mechanism of action
Results in 2010, from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.
Linagliptin may cause severe joint pain.
The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines like sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. The FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Trajenta’s Prescribing Information states the drug is contraindicated for people with bronchial hyperreactivity (for example, asthma).
Mechanism of action
Linagliptin belongs to a class of drugs called DPP-4 inhibitors.
Linagliptin is the INN.
Mechanism of Action
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta-cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.
Progress Life Sciences Pvt. Ltd. Expertise
Headquartered in Mumbai, India, Progress Life Sciences Pvt. Ltd. is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Linagliptin API. Progress Life Sciences API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Progress Life Sciences Pvt. Ltd. API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long-chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Progress Life Sciences Linagliptin API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.